New pill for high cholesterol shows promise in early trial
NCT ID NCT04079530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tested a new controlled-release version of the drug pemafibrate in 60 adults with dyslipidemia (abnormal levels of fats in the blood). The goal was to see if the new version works as well or better than the current immediate-release tablet, with fewer side effects. Participants received different doses of the drug over two periods, and researchers measured changes in triglycerides and cholesterol levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pemafibrate (a drug to lower blood fats)
What this could lead to
If successful, this could lead to a more convenient, once-daily pill for managing high triglycerides and cholesterol.
What could go wrong
This is an early Phase 2 study with only 60 participants, so results may not apply to everyone. The new controlled-release form might not work better or could have side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DYSLIPIDEMIAS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Medical Corporation Heishinkai OPHAC Hospital
Osaka, 532-0003, Japan